People
Interferons are proteins produced by the body to fight viral infections by inhibiting its replication in the body.
Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $390 per vial, which for most patients receiving a 5-day treatment using six vials, would come to $2,340 per patient.
DBV Technologies, located just outside Paris, announced it is cutting jobs while it awaits news from the U.S. Food and Drug Administration (FDA) about its application for Viaskin Peanut.
San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.
The lung model in Draper’s new organ-on-a-chip platform, PREDICT96, replicates the structure and function of human lung tissue from donors with multiple patient profiles on a 96-well plate, increasing assay throughput by 10-fold.
Despite the bleak challenges brought on by COVID-19, Bill Sibold, executive vice president of Sanofi Genzyme, is optimistic that some of the greatest discoveries in medicine and treating various diseases are within the grasp of the pharmaceutical industry.
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
The supply chain that exists for traditional pharmaceuticals is woefully insufficient for regenerative medicine, according to Robert Lechich, principal manufacturing and supply chain consultant for Global OT/IT – Quality Services.
According to a brief report by Reuters, the drug company plans to hold meetings with staff representatives tomorrow and Monday of next week to describe a restructuring plan, according to four sources familiar with the matter.
The Brisbane, California-based company announced its plans to separate the two units and treat them as individual operations with individual managers.
PRESS RELEASES